RYE, N.Y., Sept. 7 /PRNewswire/ — Curemark (www.curemark.com), a drug
research and development company focused on the treatment of
neurological diseases, announced that James F. Szigethy, formerly a
consultant for Curemark, has assumed the position of Director of
New Product Development. In his new position, Szigethy will
have direct oversight of improving existing products and directing
the development of new products. As Curemark continues to
anticipate expansion of its clinical trials program, Szigethy will
oversee and coordinate all activities across a variety of Curemark
product programs, the company said.
Dr. Joan Fallon, Curemark’s Founder and CEO said, “We are very
excited to have James assume this new position.
Curemark has a strong focus on innovation coupled with
excellence and James’ credentials as an experienced pharmacist and
consultant are a tremendous asset to us.”
“I am excited to have the opportunity to implement Curemark’s
strategic vision and this is a truly exciting company to work for,”
remarked Szigethy. “Curemark is focused on children with
conditions for whom either no treatment or inadequate treatment is
available and I am proud to be at the forefront of the development
of new products to further our studies and Curemark’s mission.”
Szigethy’s new responsibilities will include formulation
development, overseeing Curemark’s product production and expansion
of its product portfolio. He has been with the company since
2007.
Szigethy graduated from St. John’s University in 1994 with a
B.A. in Psychology. He attained his B.S. in Pharmacy in 2001 and
became a supervising pharmacist for Wal-Mart, where his department
was recognized as Wal-Mart’s Northeast Region Pharmacy of the Year
in 2006.
Curemark currently is conducting Phase III clinical trials for
CM-AT, an autism treatment that will be one of t
‘/>”/>
SOURCE
